On the evening of July 18, TaienkangAn announcement was released stating that the application for a Phase II/III seamless adaptive clinical trial for the rosacea indication of CKBA cream developed by the company's holding subsidiary, Bo Chuang Park, had recently received an acceptance notice issued by the National Medical Products Administration.

The announcement shows that rosacea is a chronic, recurrent inflammatory skin disease that occurs most frequently in women aged 20 to 50, with symptoms such as facial flushing, erythema, papules, pustules and telangiectasia. So far, there is no Class 1 innovative drug for the treatment of rosacea in China.Approved for marketing.

According to Taienkang , the company's CKBA cream is a major achievement of more than 20 years of basic research by Wang Honglin's team at Shanghai Jiaotong University. It is the world's first innovative small molecule drug targeting the T cell fatty acid metabolism pathway (by inhibiting the key enzyme ACC1/ACC2). Its unique mechanism of action is to directly attack the core of rosacea inflammation by regulating the immune response (inhibiting the differentiation of naive CD4+ T cells into Th17 cells and downregulating IL-17A expression), improving erythema and inflammatory infiltration.

Taienkang said that the successful acceptance of the Phase II/III seamless adaptive clinical trial application for CKBA cream for rosacea further verified the huge development potential of CKBA in the field of autoimmunity as the first FIC (First-in-Class, the world's first) innovative small molecule drug targeting the T-cell fatty acid metabolic pathway. The company will concentrate resources to accelerate the clinical progress of vitiligo and rosacea indications, while continuing to carry out in-depth basic research on CKBA in terms of targets and mechanisms of action, and further expand its related indications in the field of autoimmunity.
https://finance.eastmoney.com/a/202507193461805632.html